Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01274208|
Recruitment Status : Unknown
Verified November 2014 by Ari Zimran, Shaare Zedek Medical Center.
Recruitment status was: Recruiting
First Posted : January 11, 2011
Last Update Posted : November 19, 2014
- Investigate the anti-HCV response in patients with Gaucher disease(GD)
- Define the potential role of high levels of Glucocerebroside in the immune system
High levels of Glucocerebroside can be used as a tool in the antiviral treatment of hepatitis C by potentiating the immune response of natural killer T cells and dendritic cells
|Condition or disease|
|Gaucher Disease Hepatitis C|
Gaucher disease is the most common glycolipid storage disorder, caused by reduced activity of the lysosomal enzyme glucocerebrosidase, which leads to the accumulation of the substrate, glucocerebroside (GC), in the cells of the reticulo-endothelial system.
One of the hallmarks of GD is its great phenotypic heterogeneity with variable presentations and symptoms, beginning with a lethal variant of infants dying at or near birth with hydrops fetalis and ichthyoids at one extreme and totally asymptomatic individuals without any physical or laboratory abnormalities at the other extreme.
This autosomal recessive disease is pan-ethnic, but it is especially prevalent among Ashkenazi Jews. From over 300 different mutations reported in the glucocerebrosidase gene, five account for 98% of the disease-producing alleles. Of these mutations, N370S (or 1226G) occurs in 1 out of 17 Ashkenazi individuals, leading to a disease frequency of 1:850 in this ethnic group.
The high prevalence of more than a single mutation among Ashkenazi Jews and the existence of two additional rare inherited lysosomal glycolipid storage diseases, Tay Sachs and Nieman Pick, at a higher prevalence within the same ethnic group is believed to be caused by selective advantage.
Available genetic data are consistent with a founder effect(4) whereas the nature of such an advantage has not been identified.
The aim of this study was to investigate the anti-HCV immune response in patients with GD in an attempt to define the potential role of high levels of GC in the immune system and antiviral immunity.
The host metabolic background exerts a profound effect on antiviral immunity, which may influence the clinical course of chronic HCV infection.
The accumulation of GC in patients with GD may provide a selective evolutionary advantage to these patients.
Glucocerebroside was recently tested in human trials and shown to be effective in altering NKT- dependent metabolic pathways, insulin resistance, and associated liver injury.
The present study examine the capability of Glucocerebroside to be be used as a tool in the antiviral treatment of hepatitis C by potentiating the immune response of natural killer T cells and dendritic cells.
Data are presented as the mean ± standard deviation (SD). The Kruskal Wallis non-parametric ANOVA test was used to identify differences between the study groups.
The student t-test and non-parametric Mann-Whitney test were used to compare quantitative variables between the study groups as appropriate; P <0.05 was considered to be significant.
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Official Title:||Enhanced HCV Nonstructural Protein 3 (NS3) -Specific T Cell Proliferation,Interferon γ (IFNγ) and Interleukin-10 (IL-10) Secreting Clones, and Peripheral Blood Natural Killers T Cells ( NKT Cells) in Patients With Type I Gaucher Disease Infected With HCV : An Advantage in Anti Hepatitis Immunity?|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||March 2016|
|Estimated Study Completion Date :||April 2016|
|Gaucher Disease with Hepatitis C|
- Gaucher patients' immune system provide enhanced immunity against hepatitis c virus [ Time Frame: 6 months ]
- the role Glucocerebroside level have by enhanced immunity in patients with Gaucher disease [ Time Frame: 30 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01274208
|Contact: Bernardo Melamud, Dr.||email@example.com|
|Contact: Ari Zimran, Prof.||firstname.lastname@example.org|
|Shaare Zedek , Medical Center||Recruiting|
|Jerusalem, Israel, 91120|
|Contact: Melamud email@example.com|
|Contact: zimran, Prof. firstname.lastname@example.org|
|Principal Investigator: Bernardo Melamud, Dr.|
|Sub-Investigator: Ari Zimran, Prof.|
|Hadassah Medical Center||Recruiting|
|Contact: Yaron Ilan, Prof. 972 2 6778231 email@example.com|
|Sub-Investigator: Yaron Ilan, Prof.|
|Principal Investigator:||Bernardo Melamud, Dr.||Gaucher Clinic , Shaare zedek Hospital|